Parkinson Disease 4, Autosomal Dominant Lewy Body Clinical Trials

Completed

Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)

NCT03040999

Conditions: Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +6 more
Locations: UCLA Medical Center ( Site 0273) Los Angeles, California, United States

University of California San Francisco ( Site 0274) San Francisco, California, United States

St. Joseph Heritage Healthcare ( Site 0254) Santa Rosa, California, United States

Smilow Cancer Hospital at Yale New Haven ( Site 0256) New Haven, Connecticut, United States

View all 151 locations

View Trial Details

Completed

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

NCT05508867

Conditions: Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin Lymphoma, +8 more
Locations: The University of Arizona Cancer Center - North Campus ( Site 2216) Tucson, Arizona, United States

UCLA Hematology/Oncology - Santa Monica ( Site 2208) Los Angeles, California, United States

Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site Torrance, California, United States

Moffitt Cancer Center ( Site 2200) Tampa, Florida, United States

View all 105 locations

View Trial Details

Completed

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study

NCT04889118

Conditions: Malignant Melanoma, Melanoma, Neoplasms, +11 more
Locations: Beijing Cancer Hospital (0601) Beijing, Beijing Municipality, China

Fujian Provincial Cancer Hospital ( Site 0612) Fuzhou, Fujian, China

Sun Yat-Sen University Cancer Center (0602) Guangzhou, Guangdong, China

Henan Cancer Hospital ( Site 0610) Zhengzhou, Henan, China

View Trial Details

Completed

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

NCT05342636

Conditions: Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +14 more
Locations: Liga Norte Riograndense Contra o Câncer ( Site 2303) Natal, Rio Grande do Norte, Brazil

Hospital Nossa Senhora da Conceição ( Site 2301) Porto Alegre, Rio Grande do Sul, Brazil

ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 2300) São Paulo, Brazil

FALP-UIDO ( Site 2400) Santiago, Region M. de Santiago, Chile

View all 46 locations

View Trial Details

Completed

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

NCT03615326

Conditions: Digestive System Diseases, Digestive System Neoplasms, Gastric Neoplasms, +8 more
Locations: UCLA Hematology/Oncology - Westwood (Building 200 Suite 120) ( Site 0045) Los Angeles, California, United States

Pacific Cancer Care ( Site 0063) Monterey, California, United States

UC Irvine Medical Center/Chao Family Comprehensive Cancer Center ( Site 0050) Orange, California, United States

University of Miami Sylvester Comprehensive Cancer Center - Plantation ( Site 0026) Miami, Florida, United States

View all 192 locations

View Trial Details

Completed

Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

NCT04428151

Conditions: Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +6 more
Locations: City of Hope ( Site 1519) Duarte, California, United States

UCLA Hematology/Oncology - Westwood (Building 100) ( Site 1568) Los Angeles, California, United States

Yale-New Haven Hospital-Yale Cancer Center ( Site 1505) New Haven, Connecticut, United States

Georgetown University Medical Center ( Site 1520) Washington D.C., District of Columbia, United States

View all 120 locations

View Trial Details

Completed

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

NCT03358472

Conditions: Carcinoma, Carcinoma, Squamous Cell, Head and Neck Cancer, +7 more
Locations: Pacific Cancer Medical Center Anaheim, California, United States

UC Davis Comprehensive Cancer Center Sacramento, California, United States

St. Joseph Heritage Healthcare Santa Rosa, California, United States

University of Colorado Cancer Center Aurora, Colorado, United States

View all 73 locations

View Trial Details

Completed

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

NCT04704219

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +15 more
Locations: Georgetown University Medical Center ( Site 0001) Washington D.C., District of Columbia, United States

St. Vincent Frontier Cancer Center ( Site 0004) Billings, Montana, United States

Comprehensive Cancer Centers of Nevada ( Site 0010) Las Vegas, Nevada, United States

Memorial Sloan Kettering Cancer Center ( Site 0015) New York, United States

View all 56 locations

View Trial Details

Completed

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

NCT05600309

Conditions: Colonic Diseases, Colorectal Cancer, Colorectal Neoplasms, +10 more
Locations: The Second Affiliated Hospital of Anhui Medical University ( Site 1179) Hefei, Anhui, China

Chongqing Cancer Hospital ( Site 1151) Chongqing, Chongqing Municipality, China

Fujian Province Cancer Hospital ( Site 1178) Fuzhou, Fujian, China

Sun Yat-Sen University Cancer Center ( Site 1150) Guangzhou, Guangdong, China

View all 24 locations

View Trial Details

Completed

KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)

NCT04165083

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations: Banner MD Anderson Cancer Center ( Site 0001) Gilbert, Arizona, United States

City of Hope ( Site 0014) Duarte, California, United States

UCSF Medical Center at Mission Bay ( Site 0007) San Francisco, California, United States

Georgetown University ( Site 0036) Washington D.C., District of Columbia, United States

View all 39 locations

View Trial Details

Parkinson Disease 4, Autosomal Dominant Lewy Body

Parkinson Disease 4, Autosomal Dominant Lewy Body trial results

Related conditions